Adial Pharmaceuticals Faces Nasdaq Non-Compliance Notice

An update from Adial Pharmaceuticals ( (ADIL) ) is now available.

On May 23, 2025, Adial Pharmaceuticals received a notification from Nasdaq indicating non-compliance with the stockholders’ equity requirement of $2.5 million, as their equity stood at $2,126,662 as of March 31, 2025. The company plans to submit a Compliance Plan by July 7, 2025, to address this issue and potentially gain an extension to regain compliance, though there is no assurance of acceptance by Nasdaq.

The most recent analyst rating on (ADIL) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.

Spark’s Take on ADIL Stock

According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.

Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.

To see Spark’s full report on ADIL stock, click here.

More about Adial Pharmaceuticals

Adial Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for addiction and related disorders. The company is engaged in creating therapeutic solutions that address unmet medical needs in this market segment.

Average Trading Volume: 597,788

Technical Sentiment Signal: Sell

Current Market Cap: $5.44M

For a thorough assessment of ADIL stock, go to TipRanks’ Stock Analysis page.